TrialFinder  /  Landscape Report OPIOID USE DISORDER  ·  2026-07-17 Revasser  /  revasserkernel.com
Landscape Report TrialFinder
SOURCE  ClinicalTrials.gov API v2
GENERATED  2026-07-17
VERSION  v1
SAMPLE  100 of 3617 studies

opioid use disorder

The opioid use disorder clinical trial landscape includes 3617 actively recruiting trials. Semantic expansion identified 3368 additional trials beyond exact-match search, representing a 1352.6% discovery lift across related conditions and therapeutic approaches.

Recruiting
3617
active trials
Expansion Lift
+1352.6%
3368 additional trials
Top Sponsor
University of California, San Francisco
2 trials
Dominant Phase
NA
59 of 104 sampled
Pipeline Overview
Phase Distribution
NA
59
Early I
2
Phase 1
5
Phase 2
12
Phase 3
6
Phase 4
2
Other
18
Therapeutic Modalities
BEHAVIORAL
60
OTHER
29
DRUG
27
DEVICE
17
BIOLOGICAL
10
DIAGNOSTIC_TEST
5
PROCEDURE
5
Recruiting vs. Completed (2yr)
Recruiting
3617
Completed
2419
Competitive Landscape
Sponsor Classification
85%
8%
8%
OTHER (22)
INDUSTRY (2)
FED (2)
Top Sponsors
SponsorTrialsClass
University of California, San Francisco2OTHER
University of Pittsburgh2OTHER
Medical University of South Carolina2OTHER
University of California, Los Angeles2OTHER
Johns Hopkins University2OTHER
Massachusetts General Hospital2OTHER
Virginia Commonwealth University2OTHER
Cairo University2OTHER
Neurocrine Biosciences2INDUSTRY
University of Alabama at Birmingham2OTHER
VA Office of Research and Development2FED
Wake Forest University Health Sciences1OTHER
Texas A&M University1OTHER
Göteborg University1OTHER
Unity Health Toronto1OTHER
Geographic Distribution
Top U.S. States by Trial Density
StateTrialsTop City
Florida24Miami
California23Encino
Texas13College Station
Massachusetts10Boston
New York8New York
Georgia6Atlanta
Alabama5Birmingham
Ohio5Cleveland
Maryland5Baltimore
Pennsylvania5Philadelphia
South Carolina4Charleston
Utah4Salt Lake City
Connecticut4New Haven
Missouri4Saint Charles
Oklahoma4Oklahoma City
Virginia4Fairfax
Arizona3Chandler
Illinois3Chicago
Washington3Bellevue
Wisconsin3Madison
Expansion Intelligence
+1352.6%
Discovery lift — trials found by semantic expansion that exact-match search misses entirely. This is the gap competitors don't see.
3
Exact
1
Parent
3
Related
5
Comorbid
6
Therapeutic
Top Expansion Terms
  • substance use disorder Parent
  • heroin use disorder Related
  • prescription opioid misuse Related
  • fentanyl Related
  • hepatitis C Comorbid
  • HIV Comorbid
  • depression Comorbid
  • chronic pain Comorbid
  • overdose Comorbid
  • buprenorphine Therapeutic

These terms are curated from clinical literature — not generated by a language model. Each captures trials that use variant nomenclature for the same underlying condition or therapeutic area.

Key Findings
What This Landscape Means for opioid use disorder
high
Standard searches miss 1353% of relevant trials for opioid use disorder — semantic expansion across related conditions and therapeutic approaches is essential for complete landscape visibility.
3368 additional trials found via expansion vs 249 exact matches
high
6 Phase 3 trials indicate a maturing pipeline with near-term approval potential.
Phase 3 represents 6% of sampled trials
Next Steps
Take Action on This Intelligence
//
Stay Current
Get alerted when new trials open for opioid use disorder and related conditions. Free tier monitors 1 condition weekly.
Set Up Alerts
[+]
Research Portal
Deploy this intelligence as your organization's permanent research hub — auto-updating, branded, zero hosting cost.
From $497
{<}
API Access
Integrate trial intelligence into your own tools. Full expansion engine, landscape analytics, real-time data.
View Plans
Top Recruiting Trials
20 actively recruiting studies
Identifying Challenges to Healthy Aging in Persons With Human Immunodeficiency Virus (HIV) Age 50 and Older
Wake Forest University Health Sciences n=100 Atrium Health Wake Forest Baptist Winston-Salem, North Carolina
Intervention OTHER: Customized activity plan — Clients with identified challenges to successful aging (pre-frail or frail on screening) will be invited to develop an i...
Eligibility Ages 50 Years
Contact Yolanda Belin, MS · (336) 716-7079 · yolanda.belin@advocatehealth.org
NCT05959434 PHASE2
Integration of Cognitive Processing Therapy and Relapse Prevention for Alcohol Use Disorder and PTSD
Texas A&M University n=200 Medical University of South Carolina Charleston, South Carolina
Intervention BEHAVIORAL: Cognitive Processing Therapy + Relapse Prevention — Cognitive-Behavioral Therapy that integrates Cognitive Processing Therapy for PTSD with Relapse Prevention for alcohol u...
Eligibility Ages 18 Years
Contact Anka A Vujanovic, Ph.D. · 979-862-6538 · avujanovic@tamu.edu
iCBT for Seniors With Depression in Primary Care
Göteborg University n=390 University of Gothenburg Gothenburg
Intervention BEHAVIORAL: iCBT for depression — iCBT depression program with minimal therapist contact offered within 14 days from inclusion and with a duration of 10-1...
Eligibility Ages 65 Years
Contact Dominique Hange, Ass Prof · +46722 245 700 · dominique.hange@allmed.gu.se
Characterizing Dopamine Receptor Binding in Treatment Resistant Depression
Unity Health Toronto n=45 Unity Health Toronto Toronto, Ontario
Intervention DIAGNOSTIC_TEST: PET scans — PET scans and PHNO scans
Eligibility Ages 25 Years – 55 Years
Contact Sakina J Rizvi, PhD · 416-864-6060 · rizvis@smh.ca
NCT06034938 PHASE2
DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)
University Hospital, Caen n=32 CHU de Caen Caen
Intervention DRUG: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] — Switch previous therapy with DOR/TDF/3TC
Eligibility Ages 18 Years
Contact Jean-Jacques Parienti, MD, PhD · +33231064320 · parienti-jj@chu-caen.fr
NCT06902298 PHASE1, PHASE2
Personalized Ultrasonic Brain Stimulation for Depression (R61)
Brian Mickey n=30 University of Utah Salt Lake City, Utah
Intervention DEVICE: LTFUS to SCC — Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex
Eligibility Ages 18 Years – 65 Years
Contact Brian J Mickey · 801-587-0159 · brian.mickey@utah.deu
COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression
Danish Research Centre for Magnetic Resonance n=78 Centre of Neuropsychiatric Depression Research Glostrup Municipality
Intervention DEVICE: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil. — Intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC) will be administer...
Eligibility Ages 18 Years – 95 Years
Contact Poul Videbech, Professor · +4538640634 · poul.videbech@regionh.dk
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
Sunnybrook Health Sciences Centre n=88 Sunnybrook Health Sciences Centre Toronto, Ontario
Intervention DEVICE: rTMS — Accelerated iTBS treatment
Eligibility Ages 20 Years – 65 Years
Contact Anusha Baskaran, PhD · 416-480-6100 · anusha.baskaran@sunnybrook.ca
NCT06633016 PHASE2
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Autobahn Therapeutics, Inc. n=230 Autobahn Site #131 Birmingham, Alabama
Intervention DRUG: ABX-002 — ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the mor...
Eligibility Ages 18 Years – 65 Years
Contact Ashlee Heldreth, MS · 8582573418 · clinicaltrials@autobahntx.com
Enhanced Mentor Mother Strategy for Pregnant and Postpartum Women Living With HIV
Indiana University n=200 Burnt Forest Sub-District Hospital Burnt Forest, Uasin Gishu County
Intervention BEHAVIORAL: Enhanced Mentor Mother Strategy — The enhanced Mentor Mother strategy introduces a structured approach to differentiated PMTCT support, led by trained pee...
Eligibility Ages 18 Years, FEMALE only
Contact James G Carlucci, MD, MPH · +1 317 944 7260 · jimcarlu@iu.edu
NCT05988632 PHASE1, PHASE2
Intranasal Insulin for Treatment of Alcohol Use Disorder
Brown University n=40 Brown University Providence, Rhode Island
Intervention DRUG: Regular Human Insulin then Placebo — Insulin: 80 IU (administered intranasally) THEN Placebo: 0.9% saline solution (administered intranasally)
Eligibility Ages 21 Years
Contact Carolina L Haass-Koffler · 4155191385 · carolina_haass-koffler@brown.edu
Prepping for The Talk: Helping Trusted Adults and Youth Talk About Sexual Health
Rhode Island Hospital n=40 Rhode Island Hospital Providence, Rhode Island
Intervention BEHAVIORAL: Intervention — Youth: interventionist-facilitated 1:1 conversation with the youth via videoconference that includes a) brief sexual hea...
Eligibility Ages 14 Years – 17 Years, MALE only
Contact Jack Rusley, MD, MHS · 401-444-5980 · jack.rusley@brownhealth.org
Internet-Delivered Cognitive Behaviour Therapy for PTSD Among Public Safety Personnel
University of Regina n=300 Department of Psychology and Collaborative Centre for Justice and Safety Regina, Saskatchewan
Intervention BEHAVIORAL: PSP PTSD Course — A tailored ICBT intervention designed to treat symptoms of PTSD will be delivered to public safety personnel. Clients wi...
Eligibility Ages 18 Years
Contact Heather D Hadjistavropoulos, PhD · 306-585-5133 · heather.hadjistavropoulos@uregina.ca
B.R.A.I.N in People Living With HIV Study
University of Cape Town n=43 Michael Mapongwana Community Health Clinic Cape Town, Western Cape
Intervention BEHAVIORAL: Combined Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ© — The intervention combines Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ. This integrate...
Eligibility Ages 30 Years – 50 Years
Contact Hetta Gouse, PhD · +642102064321 · hetta.gouse@uct.ac.za
NCT06205056 PHASE1
Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults
U.S. Army Medical Research and Development Command n=78 Makerere University Walter Reed Project (MUWRP) Kampala
Intervention BIOLOGICAL: Ad26.Mos4.HIV in CH505 TF chTrimer + ALFQ [Arm 1a] — Participants in Arm 1a will receive dose consistent injections (5x10\^10 vp/0.5 mL) of Ad26.Mos4.HIV in a 0.5 mL injecti...
Eligibility Ages 18 Years – 50 Years
Contact Grace Mirembe, MBChB, MMed · +256 312 330400 · gmirembe@muwrp.org
NCT07412756 PHASE3
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Eli Lilly and Company n=1000 Accellacare - Moorpark Moorpark, California
Intervention DRUG: Brenipatide — Administered SC
Eligibility Ages 18 Years – 75 Years
Contact Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
NCT06248710 PHASE2, PHASE3
Dog Presence and Oxytocin on Trust Towards Therapists
Dr. Karin Hediger n=176 University of Basel Basel, Canton of Basel-City
Intervention DRUG: Oxytocin nasal spray — Syntocinon nose spray is usually applied in the context of labour and breast feeding. In this study, however, it will be...
Eligibility Ages 18 Years
Contact Karin Hediger, Prof. Dr. · +41 (0)61 207 65 80 · elena.pauli@unibas.ch
NCT06793488 EARLY_PHASE1
Anxiety During Abstinence in AUD
Columbia University n=60 Columbia University Irving Medical Center New York, New York
Intervention DRUG: Disulfiram 250 mg — Disulfiram will be used in Participants with Alcohol Use Disorder only to facilitate abstinence.
Eligibility Ages 21 Years – 55 Years
Contact A B Srivastava, MD · 646-774-8189 · abs2257@cumc.columbia.edu
Effectiveness of an Online Biopsychosocial Intervention to Improve Well-being and Mental Health During Pregnancy
University Rovira i Virgili n=228 Centre d'Atenció Primària Sant Pere Reus, Tarragona
Intervention OTHER: Biopsychosocial Cognitive Behavioral Intervention — The study intervention is based on a biopsychosocial approach (considers the interaction between: biological factors suc...
Eligibility Ages 18 Years, FEMALE only
Contact Carmen Hernández Martínez, Doctor · +34675245881 · carmen.hernandez@urv.cat
Translation and Validation of the Limbs, Pain, Autonomy, Depression, Anxiety and Quality of Life Scales in Albanian
Universidad Católica San Antonio de Murcia n=300 Jasemin Todri Murcia, Murcia
Eligibility Ages 18 Years – 80 Years